Stem cell ophthalmology treatment study (SCOTS) for retinal and optic nerve diseases

A preliminary report

Jeffrey N. Weiss, Steven Levy, Alexis Malkin

Research output: Contribution to journalArticle

Abstract

In this report, we present the results of a single patient with optic neuroprotective and immunomodulatory effects and havean important role in the treatment of nervous tissue diseaseincluding retinal and optic nerve diseases through brain-derivedneurotrophic factor as reported by Wilkins et al. (2009).Methodology of SCOTSSCOTS, the Stem Cell Ophthalmology Treatment Study, is thelargest ophthalmology stem cell study registered at the NationalInstitutes of Health: Identifier NCT Number 01920867 SCOTS is an open label, non-randomized, efficacy study.There is no placebo or sham arm. All patients enrolled in thestudy meet eligibility criteria and receive active treatment.Bone marrow aspirated from the posterior iliac crest is separatedto provide BMSCs within the stem cell concentrate.Inclusion criteria for SCOTS include that patients should• Have objective, documented damage to the retina or opticnerve unlikely to improve OR.• Have objective, documented damage to the retina or opticnerve that is progressive.• AND have less than or equal to 20/40 best corrected centralvisual acuity in one or both eyes AND/OR an abnormalAbstractIn this report, we present the results of a single patient with optic neuropathy treated within theStem Cell Ophthalmology Treatment Study (SCOTS). SCOTS is an Institutional Review Boardapproved clinical trial and is the largest ophthalmology stem cell study registered at the NationalInstitutes of Health to date- www.clinicaltrials.gov Identifier NCT 01920867. SCOTS utilizesautologous bone marrow-derived stem cells in the treatment of optic nerve and retinal diseases.Pre- and post-treatment comprehensive eye exams were independently performed at the WilmerEye Institute at the Johns Hopkins Hospital, USA. A 27 year old female patient had lost visionapproximately 5 years prior to enrollment in SCOTS. Pre-treatment best-corrected visual acuityat the Wilmer Eye Institute was 20/800 Right Eye (OD) and 20/4,000 Left Eye (OS). Four monthsfollowing treatment in SCOTS, the central visual acuity had improved to 20/100 OD and 20/40OS.

Original languageEnglish (US)
Pages (from-to)982-988
Number of pages7
JournalNeural Regeneration Research
Volume10
Issue number6
DOIs
StatePublished - Jun 1 2015

Fingerprint

Optic Nerve Diseases
Ophthalmology
Stem Cells
Therapeutics
Retina
Bone Marrow
Nerve Tissue
Retinal Diseases
Health
Neuroprotective Agents

Keywords

  • Blindness
  • Bone marrow-derived stem cells
  • Ophthalmology
  • Optic nerve
  • Optic neuropathy
  • Stem cells
  • Visual loss

ASJC Scopus subject areas

  • Developmental Neuroscience

Cite this

Stem cell ophthalmology treatment study (SCOTS) for retinal and optic nerve diseases : A preliminary report. / Weiss, Jeffrey N.; Levy, Steven; Malkin, Alexis.

In: Neural Regeneration Research, Vol. 10, No. 6, 01.06.2015, p. 982-988.

Research output: Contribution to journalArticle

Weiss, Jeffrey N. ; Levy, Steven ; Malkin, Alexis. / Stem cell ophthalmology treatment study (SCOTS) for retinal and optic nerve diseases : A preliminary report. In: Neural Regeneration Research. 2015 ; Vol. 10, No. 6. pp. 982-988.
@article{290ea98a37304f648d3797266b13285c,
title = "Stem cell ophthalmology treatment study (SCOTS) for retinal and optic nerve diseases: A preliminary report",
abstract = "In this report, we present the results of a single patient with optic neuroprotective and immunomodulatory effects and havean important role in the treatment of nervous tissue diseaseincluding retinal and optic nerve diseases through brain-derivedneurotrophic factor as reported by Wilkins et al. (2009).Methodology of SCOTSSCOTS, the Stem Cell Ophthalmology Treatment Study, is thelargest ophthalmology stem cell study registered at the NationalInstitutes of Health: Identifier NCT Number 01920867 SCOTS is an open label, non-randomized, efficacy study.There is no placebo or sham arm. All patients enrolled in thestudy meet eligibility criteria and receive active treatment.Bone marrow aspirated from the posterior iliac crest is separatedto provide BMSCs within the stem cell concentrate.Inclusion criteria for SCOTS include that patients should• Have objective, documented damage to the retina or opticnerve unlikely to improve OR.• Have objective, documented damage to the retina or opticnerve that is progressive.• AND have less than or equal to 20/40 best corrected centralvisual acuity in one or both eyes AND/OR an abnormalAbstractIn this report, we present the results of a single patient with optic neuropathy treated within theStem Cell Ophthalmology Treatment Study (SCOTS). SCOTS is an Institutional Review Boardapproved clinical trial and is the largest ophthalmology stem cell study registered at the NationalInstitutes of Health to date- www.clinicaltrials.gov Identifier NCT 01920867. SCOTS utilizesautologous bone marrow-derived stem cells in the treatment of optic nerve and retinal diseases.Pre- and post-treatment comprehensive eye exams were independently performed at the WilmerEye Institute at the Johns Hopkins Hospital, USA. A 27 year old female patient had lost visionapproximately 5 years prior to enrollment in SCOTS. Pre-treatment best-corrected visual acuityat the Wilmer Eye Institute was 20/800 Right Eye (OD) and 20/4,000 Left Eye (OS). Four monthsfollowing treatment in SCOTS, the central visual acuity had improved to 20/100 OD and 20/40OS.",
keywords = "Blindness, Bone marrow-derived stem cells, Ophthalmology, Optic nerve, Optic neuropathy, Stem cells, Visual loss",
author = "Weiss, {Jeffrey N.} and Steven Levy and Alexis Malkin",
year = "2015",
month = "6",
day = "1",
doi = "10.4103/1673-5374.158365",
language = "English (US)",
volume = "10",
pages = "982--988",
journal = "Neural Regeneration Research",
issn = "1673-5374",
publisher = "Editorial Board of Neural Regeneration Research",
number = "6",

}

TY - JOUR

T1 - Stem cell ophthalmology treatment study (SCOTS) for retinal and optic nerve diseases

T2 - A preliminary report

AU - Weiss, Jeffrey N.

AU - Levy, Steven

AU - Malkin, Alexis

PY - 2015/6/1

Y1 - 2015/6/1

N2 - In this report, we present the results of a single patient with optic neuroprotective and immunomodulatory effects and havean important role in the treatment of nervous tissue diseaseincluding retinal and optic nerve diseases through brain-derivedneurotrophic factor as reported by Wilkins et al. (2009).Methodology of SCOTSSCOTS, the Stem Cell Ophthalmology Treatment Study, is thelargest ophthalmology stem cell study registered at the NationalInstitutes of Health: Identifier NCT Number 01920867 SCOTS is an open label, non-randomized, efficacy study.There is no placebo or sham arm. All patients enrolled in thestudy meet eligibility criteria and receive active treatment.Bone marrow aspirated from the posterior iliac crest is separatedto provide BMSCs within the stem cell concentrate.Inclusion criteria for SCOTS include that patients should• Have objective, documented damage to the retina or opticnerve unlikely to improve OR.• Have objective, documented damage to the retina or opticnerve that is progressive.• AND have less than or equal to 20/40 best corrected centralvisual acuity in one or both eyes AND/OR an abnormalAbstractIn this report, we present the results of a single patient with optic neuropathy treated within theStem Cell Ophthalmology Treatment Study (SCOTS). SCOTS is an Institutional Review Boardapproved clinical trial and is the largest ophthalmology stem cell study registered at the NationalInstitutes of Health to date- www.clinicaltrials.gov Identifier NCT 01920867. SCOTS utilizesautologous bone marrow-derived stem cells in the treatment of optic nerve and retinal diseases.Pre- and post-treatment comprehensive eye exams were independently performed at the WilmerEye Institute at the Johns Hopkins Hospital, USA. A 27 year old female patient had lost visionapproximately 5 years prior to enrollment in SCOTS. Pre-treatment best-corrected visual acuityat the Wilmer Eye Institute was 20/800 Right Eye (OD) and 20/4,000 Left Eye (OS). Four monthsfollowing treatment in SCOTS, the central visual acuity had improved to 20/100 OD and 20/40OS.

AB - In this report, we present the results of a single patient with optic neuroprotective and immunomodulatory effects and havean important role in the treatment of nervous tissue diseaseincluding retinal and optic nerve diseases through brain-derivedneurotrophic factor as reported by Wilkins et al. (2009).Methodology of SCOTSSCOTS, the Stem Cell Ophthalmology Treatment Study, is thelargest ophthalmology stem cell study registered at the NationalInstitutes of Health: Identifier NCT Number 01920867 SCOTS is an open label, non-randomized, efficacy study.There is no placebo or sham arm. All patients enrolled in thestudy meet eligibility criteria and receive active treatment.Bone marrow aspirated from the posterior iliac crest is separatedto provide BMSCs within the stem cell concentrate.Inclusion criteria for SCOTS include that patients should• Have objective, documented damage to the retina or opticnerve unlikely to improve OR.• Have objective, documented damage to the retina or opticnerve that is progressive.• AND have less than or equal to 20/40 best corrected centralvisual acuity in one or both eyes AND/OR an abnormalAbstractIn this report, we present the results of a single patient with optic neuropathy treated within theStem Cell Ophthalmology Treatment Study (SCOTS). SCOTS is an Institutional Review Boardapproved clinical trial and is the largest ophthalmology stem cell study registered at the NationalInstitutes of Health to date- www.clinicaltrials.gov Identifier NCT 01920867. SCOTS utilizesautologous bone marrow-derived stem cells in the treatment of optic nerve and retinal diseases.Pre- and post-treatment comprehensive eye exams were independently performed at the WilmerEye Institute at the Johns Hopkins Hospital, USA. A 27 year old female patient had lost visionapproximately 5 years prior to enrollment in SCOTS. Pre-treatment best-corrected visual acuityat the Wilmer Eye Institute was 20/800 Right Eye (OD) and 20/4,000 Left Eye (OS). Four monthsfollowing treatment in SCOTS, the central visual acuity had improved to 20/100 OD and 20/40OS.

KW - Blindness

KW - Bone marrow-derived stem cells

KW - Ophthalmology

KW - Optic nerve

KW - Optic neuropathy

KW - Stem cells

KW - Visual loss

UR - http://www.scopus.com/inward/record.url?scp=84934754334&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84934754334&partnerID=8YFLogxK

U2 - 10.4103/1673-5374.158365

DO - 10.4103/1673-5374.158365

M3 - Article

VL - 10

SP - 982

EP - 988

JO - Neural Regeneration Research

JF - Neural Regeneration Research

SN - 1673-5374

IS - 6

ER -